Showing posts with label active against native and mutated forms of the BCR–ABL oncogene in Philadelphia chromosome (Ph)-positive leukaemias. Show all posts
Showing posts with label active against native and mutated forms of the BCR–ABL oncogene in Philadelphia chromosome (Ph)-positive leukaemias. Show all posts
Friday, March 27, 2015

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

›
PF-114, a selective tyrosine kinase inhibitor (TKI), is active against native and mutated forms of the BCR–ABL oncogene in Philade...